CAJ | 학술논문

目的：比较培美曲塞及紫杉醇分别联合奈达铂二线治疗女性肺腺癌的临床疗效特点及毒副反应。方法82例一线治疗失败或复发的女性肺腺癌患者,随机分成两组,每组41例；培美曲塞组：给予5个周期以上培美曲塞(500 mg/m2, d1)联合奈达铂(50 mg/m2,d1),21 d为1周期；紫杉醇组：给予5周期以上紫杉醇(80 mg/m2,每周)联合奈达铂(50 mg/m2,d1),21 d为1周期。结果培美曲塞组和紫杉醇组的疾病控制率分别为87．8%和70．7%,中位无疾病进展时间分别为11．2个月和8．5个月。培美曲塞组中伴有不同程度胸腔积液患者在化疗结束时,胸腔积液症状完全缓解。结论培美曲塞较紫杉醇联合奈达铂对一线治疗失败的女性肺腺癌患者的近期疗效更好,特别是可使伴有恶性胸腔积液并发症的患者临床获益,且毒副反应可耐受。
목적：비교배미곡새급자삼순분별연합내체박이선치료녀성폐선암적림상료효특점급독부반응。방법82례일선치료실패혹복발적녀성폐선암환자,수궤분성량조,매조41례；배미곡새조：급여5개주기이상배미곡새(500 mg/m2, d1)연합내체박(50 mg/m2,d1),21 d위1주기；자삼순조：급여5주기이상자삼순(80 mg/m2,매주)연합내체박(50 mg/m2,d1),21 d위1주기。결과배미곡새조화자삼순조적질병공제솔분별위87．8%화70．7%,중위무질병진전시간분별위11．2개월화8．5개월。배미곡새조중반유불동정도흉강적액환자재화료결속시,흉강적액증상완전완해。결론배미곡새교자삼순연합내체박대일선치료실패적녀성폐선암환자적근기료효경호,특별시가사반유악성흉강적액병발증적환자림상획익,차독부반응가내수。
Objective To observe and appraise the efficacy and safety of pemetrexed or paclitaxel combined with nedaplatin as second-line therapy for female patients with lung adenocarcinoma. Methods 82 female patients with lung adenocarcinoma, who accepted a first-line chemotherapy failed, were selected and randomized into two groups. The pemetrexed group was given pemetrexed (500 mg/m2 , d1) and nedaplatin (50 mg/m2 , d1) more than five treatment cycles, and the paclitaxel group received paclitaxel (80 mg/m2 , 1week) and nedaplatin (50 mg/m2 , d1). Results The disease control rates were 87. 8% and 70. 7% respectively in the pemetrexed group and the pa-clitaxel group. The median progression-free survival time was 11. 2 months and 8. 5 months in the two groups. Com-pared to the paclitaxel group, the patients had various degrees of pleural effusion at the end of chemotherapy in the pemetrexed group. Conclusion Pemetrexed combined with nedaplatin as a second-line therapy has better short-term curative effect in the treatment of female patients with lung adenocarcinoma, especially those with malignant pleural effusion.